Serina Therapeutics, Inc.
SER · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $61,625 | $55,317 | $44,344 |
| - Cash | $8,620 | $6,041 | $4,267 | $3,672 |
| + Debt | $148 | $185 | $227 | $268 |
| Enterprise Value | – | $55,769 | $51,277 | $40,940 |
| Revenue | $0 | $130 | $0 | -$14 |
| % Growth | -100% | – | 100% | – |
| Gross Profit | -$17 | $114 | -$17 | -$14 |
| % Margin | – | 87.7% | – | 100% |
| EBITDA | -$4,572 | -$6,437 | -$4,805 | -$2,679 |
| % Margin | – | -4,951.5% | – | 19,135.7% |
| Net Income | -$4,585 | -$6,448 | -$4,813 | -$2,740 |
| % Margin | – | -4,960% | – | 19,571.4% |
| EPS Diluted | -0.444 | -0.64 | -0.493 | -0.25 |
| % Growth | 30.7% | -29.7% | -97.3% | – |
| Operating Cash Flow | -$3,850 | -$3,750 | -$4,322 | -$4,589 |
| Capital Expenditures | -$13 | $0 | $0 | -$5 |
| Free Cash Flow | -$3,863 | -$3,750 | -$4,322 | -$4,594 |